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Dr Michael J. Mack (Dallas, Tex). My conflict of interest
disclosure is that I am a member of the Partner trial and therefore
I am a consultant to Edwards Lifesciences (Irvine, Calif).
I would like to congratulate the team in Vancouver for their
pioneering efforts, not only Dr Ye but also Drs Anson Cheung
and John Webb. I would like to highlight some of their experience
and ask 4 questions.
Jian, your series comprises 71 patients at a mean follow-up
of 12.9 months. The 30-day mortality is 16.9% with an STS pre-
dicted mortality of 12.5%. Two-year survival is 66% and 3-year
survival is 58%. I think this needs to be put in a context that every-
body needs to understand: this is an integrated program with the1112 The Journal of Thoracic and Cardiovascular Surtransfemoral approach, and this is a ‘‘transfemoral first’’ program
so that the patients in whom the transapical approach was used in
a way are the ‘‘worst of the worst.’’ Not only are they patients
who are in inoperable condition or at very high risk for surgery,
but they are not candidates for the transfemoral approach either.
Thus, in a way you have had to develop this procedure on the pa-
tients in the worst condition.
First question: In the first 15 patients, you have highlighted that
there is a 33% mortality and that that was due to the learning curve.
What have you learned so that the rest of us can avoid that learning
curve? Is it patient selection? Is it specific aspects of the technique?
Is it early-stage technology? What are the specific learning curves
that the rest of us can avoid?
Dr Ye. Thank you very much for your comments. I would like to
make several points to emphasize in avoiding complications and
the learning curve.
1. Patient selection: I think some really ill and elderly patients
with end-stage organ diseases should not be recommended for
this procedure because correcting aortic stenosis would not neces-
sarily reverse their poor outcome.
2. Hybrid operating room with a high-quality imaging system:
We performed our initial cases in our regular operating room
with a portable C-arm fluoroscope that provides suboptimal images
during the procedure. A hybrid operating room with a high-quality
imaging system improves optimal positioning of transcatheter
valves and success rate of the procedure.
3. Surgical technique: Surgical technique is particularly impor-
tant in avoiding fatal complications, such asmassive apical bleeding.
4. Performers’ experience and knowledge and team work:
Performers should understand potential major complications and
appropriate ways to deal with these complications on an emergency
basis.
5. Postoperative care: These are really sick patients and the
postoperative care is extremely important, especially in preventing
and managing pneumonia, line infection, sepsis, or acute renal fail-
ure. In this cohort of patients, infection, particularly pneumonia,
frequently contributes to poor outcomes. Prevention of deep vein
thrombosis and pulmonary embolism is particularly important in
these elderly patients because they are frequently immobile.
DrMack. Second question: This is a transfemoral first program.
What percent of the transcatheter valves are performed by a transfe-
moral approach and what percent by a transapical one? As the trans-
femoral delivery systems get smaller, more steerable, with more
low-profile nose cones, what do you see as the ultimate role of
the transapical approach?
Dr Ye. Great questions. At our centers, approximately two
thirds and one third of accepted patients for transcatheter AVI un-
derwent the transfemoral and transapical approaches, respec-
tively. At this point, there is no evidence to suggest one
approach is better than another approach. Continuing improve-
ment in the transfemoral delivery systems might change the
role of the transapical approach. However, I believe both ap-
proaches will be advanced simultaneously as each approach has
its own advantages and disadvantages. At present, the transapical
approach is usually performed by thoracic surgeons and the trans-
femoral mainly by cardiologists. Inasmuch as I am a cardiac sur-
geon, it may be biased for me to answer your question. I believe
that the transapical approach will continue to play an importantgery c May 2010
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Drole in transcatheter valve therapy because it has unique advan-
tages compared with the transfemoral approach: (1) a shorter
and straight route to approach heart valves, which provides better
stabilization, coaxial alignment, and positioning relative to the
transfemoral approach; (2) a better way for aortic valve implanta-
tion in patients with previous mitral valve replacement because
stabilization is more important in these patients given high risks
of displacement of the balloon during valve deployment (inflating
balloon against a strut of mitral prosthesis); (3) an optimal ap-
proach for aortic valve-in-valve implantation into failed biopros-
theses; and (4) an optimal approach to access the mitral valve.
We have performed more than 10 cases of transapical valve-in-
valve implantation into failed bioprostheses at the mitral, aortic,
and the tricuspid positions. At present, the transapical approach
is the only way for valve-in-valve implantation. Therefore, I be-
lieve the transapical will continue to play a major role in this
evolving transcatheter technology. There is no randomized trial
to compare the transfemoral and transapical approaches at this
time, and the patient populations in the transapical and transfe-
moral groups are quite different, as Dr Mack mentioned. At
this point, no one is able to claim that transfemoral is better
than transapical because the populations in these 2 groups are
very different. I think a randomized controlled clinical trial toThe Journal of Thoracic and Carcompare surgery, transfemoral, and transapical approaches is
necessary.
Dr Mack. If you had to start a transcatheter valve program all
over again knowing what you know right now, would it be a trans-
apical first or transfemoral first? Second, if you had an elderly
relative, 90 years old, STS risk of 10, would you recommend con-
ventional surgery, transapical, or transfemoral?
Dr Ye. Those are excellent questions. I think the transapical
approach is pretty safe. More important, it provides a better posi-
tioning and stabilization during valve implantation. To start a pro-
gram, I think there is no reason that we cannot start the transapical
first. With development of apical closure devices, the transapical
could become a better approach.
Regarding the second part of your question on the therapeutic
option for a 90-year-old patient with aortic stenosis, I think it is dif-
ficult to give a definite answer at this moment because no random-
ized trial has been performed to compare surgical, transfemoral,
and transapical. Personally, I would not make a recommendation
just based on the age and STS score, without my assessment of
the patient. Generally speaking, for a patient 90 years old or great-
er, I would recommend either the transapical or transfemoral ap-
proach unless the patient is in very good condition with limited
comorbidities.diovascular Surgery c Volume 139, Number 5 1113
